Patents Represented by Attorney Cozette M. McAvoy

Find this attorney in the Justia Lawyer Directory

  • Deamidated interferon-?
    Patent number: 7595040
    Abstract: Interferon-? protein analogs in which the asparagine at position 25, numbered in accordance with native interferon-?, is deamidated exhibit a biological activity of native human interferon-? at an increased level and do not require HA for protein stabilization. The deamidated product is suitable for large scale manufacturing for incorporation in HA-containing or HA-free therapeutics for treatment of diseases including multiple sclerosis. An endoproteinase-C peptide map technique that produces a fingerprint profile for proteins using an enzymatic digest followed by RP-HPLC is also useful in quality control as an ID and/or quantitative test for the deamidated products.
    Type: Grant
    Filed: November 10, 2005
    Date of Patent: September 29, 2009
    Assignee: Novartis Vaccines And Diagnostics, Inc.
    Inventors: Kenji Furuya, Deborah Johnson-Jackson, Diana Tierra Ruscio
  • Methods of protein purification and recovery
    Patent number: 7544354
    Abstract: Improved methods for purification and recovery of interferon-beta (IFN-?) and compositions comprising substantially monomeric IFN-? are provided. In one purification method, substantially purified IFN-? or variant thereof is precipitated and then dissolved in a guanidine hydrochloride (HCl) solution. Renaturation of the protein occurs by dilution with a suitable buffer. A similar purification method absent the precipitation step is also provided. Following renaturation of the IFN-?, residual guanidine HCl is removed by diafiltration or dialysis with a pharmaceutically acceptable buffer to prepare pharmaceutical compositions comprising substantially monomeric IFN-?.
    Type: Grant
    Filed: October 25, 2001
    Date of Patent: June 9, 2009
    Assignee: Novartis Vaccines and Diagnostics
    Inventors: Sidney N. Wolfe, Bret A. Shirley, Susan Babuka, Dennis Fordham, Irina Esikova
  • Aminopropanol derivatives
    Patent number: 7528120
    Abstract: Compounds of formula I: wherein R1, R2, n and m are as defined in the specification, processes for their production, their uses and pharmaceutical compositions containing them.
    Type: Grant
    Filed: August 27, 2004
    Date of Patent: May 5, 2009
    Assignee: Novartis AG
    Inventors: Rainer Albert, Eric Francotte, Frédéric Zecri, Markus Zollinger
  • HSA-free formulations of interferon-beta
    Patent number: 7399463
    Abstract: Stabilized pharmaceutical compositions comprising substantially monomeric interferon-beta (IFN-?) and methods useful in their preparation are provided. The compositions comprise the IFN-? solubilized in a low-ionic-strength formulation that maintains the composition at a pH of about 3.0 to about 5.0. Methods for preparing these compositions, and for increasing solubility of IFN-? in pharmaceutical compositions, are provided.
    Type: Grant
    Filed: April 9, 2004
    Date of Patent: July 15, 2008
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Bret A. Shirley, Susan Babuka, Bao-Lu Chen, Maninder Hora, Minna Choe, Melanie Tellers
  • Quinoline derivatives
    Patent number: 7399768
    Abstract: The present invention relates to novel benzo [g] quinoline derivatives, their preparation, their use as pharmaceuticals for use in the treatment of glaucoma and myopia.
    Type: Grant
    Filed: March 6, 2003
    Date of Patent: July 15, 2008
    Assignee: Novartis AG
    Inventors: Peter Gull, Esteban Pombo Villar
  • HSA-free formulations of interferon-?
    Patent number: 7371373
    Abstract: Stabilized pharmaceutical compositions comprising substantially monomeric interferon-beta (IFN-?) and methods useful in their preparation are provided. The compositions comprise the IFN-? solubilized in a low-ionic-strength formulation that maintains the composition at a pH of about 3.0 to about 5.0. Methods for preparing these compositions, and for increasing solubility of IFN-? in pharmaceutical compositions, are provided.
    Type: Grant
    Filed: February 18, 2005
    Date of Patent: May 13, 2008
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Bret A. Shirley, Susan Babuka, Bao-Lu Chen, Maninder Hora, Minna Choe, Melanie Tellers
  • Acetylene derivatives having mGluR 5 antagonistic activity
    Patent number: 7348353
    Abstract: The invention provides compounds of formula (I) wherein m, n, A, R, R?, R?, R0, X and Y are as defined in the description, and their preparation. The compounds of formula (I) are useful as pharmaceuticals in the treatment of e.g.
    Type: Grant
    Filed: December 3, 2002
    Date of Patent: March 25, 2008
    Assignee: Novartis AG
    Inventors: Fabrizio Gasparini, Yves Auberson, Silvio Ofner